… identifier pending).2 The trial will also include patients … which patients will receive cyclophosphamide alone for lymphodepletion and … development and the chief medical officer at Allogene.1 … FDA orphan drug designation for its ULSC program for the treatment …

… ALLO), a clinical-stage biotechnology company pioneering the development of … AlloCAR T™) products for cancer and autoimmune disease, today … Food and Drug Administration (FDA) for the treatment of adult … using a dose of cyclophosphamide alone, which is used …

… 2 ACCESS trial (NCT04904588).1 The ACCESS trial assessed posttransplant cyclophosphamide as graft … approach in providing life-saving treatment, particularly for ethnically diverse … underrepresented in bone marrow transplant trials due to various barriers. …

… doctors, the mum-of-three discovered the lump was breast cancer … Tumi underwent gruelling treatment involving a … treatment called ECT – a combination of three drugs including cyclophosphamide and docetaxel which Cancer … I think my cancer treatment changed his …

… advancements in autoimmune research, effective treatment options for SLE remain limited … explore the efficacy of Cyclophosphamide—a standard treatment for SLE—within this … ultimately contributing to more effective treatment strategies for patients living with …

… , dexamethasone, doxorubicin, cyclophosphamide, and vincristine) alternated … trial (NCT02858804), which were published in Cancer Biology & Medicine … trials. The open-label, nonrandomized BDH-MCL01 trial … n = 11), treatment-related secondary leukemia …

… and Cellular Therapy, Division of Cancer Medicine at The University of Texas … Anderson Cancer Center, discusses promising findings from a phase 2 trial … evaluating the JAK inhibitor itacitinib (INCB039110) combined with post-transplant cyclophosphamide …

… Medical Association showed that when taken with glucocorticoids for induction treatment … extensive, long-term clinical trials with mizoribine, though. … against IV cyclophosphamide as induction treatment for Chinese … for inclusion. The trial concluded on March …

… proteasome inhibitors and immunomodulatory drugs, are factors, with … intensive chemotherapy, high-dose cyclophosphamide, levodopa or plasmapheresis. … oncologists and academic treatment centers should partner … trials are ongoing. For more news on cancer …

… at the University Medical Center Hamburg-Eppendorf … involvement in 18%. Treatment consisted of 4 … chemotherapy incorporating hyperfractionated cyclophosphamide/ifosfamide, … relationships with various pharmaceutical companies. Additional disclosures …